Alvotech (ALVO)
NASDAQ: ALVO
· Real-Time Price · USD
10.30
0.62 (6.40%)
At close: May 12, 2025, 3:09 PM
Alvotech Revenue Breakdown
| Period Ending | Dec 31, 2023 |
|---|---|
| Humira Revenue | 12.2B |
| Humira Revenue Growth | n/a |
Operating Expense Breakdown
| Period Ending | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Aug 31, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 15.02M | 16.88M | 14.07M | 15.49M | 18M | 16.65M | 19.71M | 22.2M | 30.22M | 17.37M | 114.97M | 24.17M | -22.17M | 19.94M | 573.8K | 545.56K | 235.33K | 14.73M | 14.73M | 14.73M | 12.14M | 12.14M | 12.14M | 12.14M |
| Selling, General, and Administrative Revenue Growth | -11.03% | +20.01% | -9.18% | -13.96% | +8.13% | -15.54% | -11.20% | -26.55% | +73.96% | -84.89% | +375.63% | -209.03% | -211.16% | +3375.76% | +5.18% | +131.82% | -98.40% | 0.00% | 0.00% | +21.31% | 0.00% | 0.00% | 0.00% | n/a |
| Research and Development Revenue | 40.26M | 33.57M | 47.61M | 49.87M | 58.01M | 53.23M | 48.72M | 50.86M | 47.48M | 46.26M | 39.75M | 47.14M | 44.4M | 56.2M | 45.2M | 45.2M | 37.02M | 37.02M | 37.02M | 37.02M | 23.89M | 23.89M | 23.89M | 23.89M |
| Research and Development Revenue Growth | +19.93% | -29.49% | -4.53% | -14.04% | +8.99% | +9.26% | -4.22% | +7.12% | +2.65% | +16.38% | -15.68% | +6.16% | -21.00% | +24.34% | 0.00% | +22.11% | 0.00% | 0.00% | 0.00% | +54.96% | 0.00% | 0.00% | 0.00% | n/a |